AnHorn Medicines

Private

TaipeiHealthcare & Life Scienceshttps://www.anhornmed.com/

Last Round

Series A

Apr 25, 2023

Total Funding Raised

$10M

Company Overview

AnHorn Medicines is a clinical-stage biotechnology company developing first-in-class and best-in-class drugs for cancers, autoimmune diseases, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small molecule drug discoveryAI drug discoveryclinical-stage biotechtechbioallosteric modulationnon-small cell lung cancerNSCLConcologyEGFR inhibitorsbrain-penetrant drugstyrosine kinase inhibitorTKIdrug resistanceprecision medicinegenerative AI drug discoverybrain metastasisbiotech out-licensingneurodegenerative diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AnHorn Medicines Comps

Public and private peers based on sector, stage, and business model.

AnHorn Medicines comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AnHorn Medicines Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Apr 25, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Chu-Chiang Lin

Chief Executive Officer

Executive Team

AnHorn Medicines Investors

Notable investors and investment history

AnHorn Medicines investors
Investor	Rounds
National Chiao Tung University Angel Club	Series A
TaiAn Technologies Corp.	Series A
Taiwania Capital	Series A
Black Marble Capital Management	Series A
Industrial Technology Investment Corporation	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 2, 2026
Monthly visitors increased 46% MoM, reaching 1.2K.
Sep 6, 2025
Grew 23% QoQ, from 13 to 16 employees.

View all signals

AnHorn Medicines Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

AnHorn Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AnHorn Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersTaipei

Employee Range12

Year Founded2017

Last FundingApr 25, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.